
Ainos, a Nasdaq-traded company with a market capitalization of $10 million, has relocated its corporate office from San Diego to the Galleria area of Houston.
The company is a dual platform AI and biotech company pioneering smelltech and immune therapeutics. The company was originally formed as Amarillo Biosciences in 1984. In 2021, it changed its name to Ainos, following a takeover by Taiwan Carbon Nano Technology Corporation. Most of its employees are based in Taiwan.
The core technology is an AI-based electronic sensory system for smells that integrates gas sensor arrays with proprietary artificial intelligence models to digitize scents into machine-readable data format. The company believes that there are many industrial applications where real-time sensing and anomaly detection is important.
In the first quarter, Ainos received an initial order for 1,400 AI Nose systems worth $2.1 million from a semiconductor manufacturer. The initial order is to be delivered over three years. If successful, 20,000 AI Noses in total, could be eventually be deployed with that customer.
Separately, the company is continuing to develop a low-dose oral interferon platform targeting selected rare, autoimmune and infectious disease indications.
In 2025, the company had revenues of $124,000 and a net loss of $15 million.
Chairman and CEO Chun-Hsien (‘Eddy’) Tsai is based in Taiwan. So is CFO Hsin-Liang (‘Christopher’) Lee, who is licensed as a CPA in the United States.
You can see the complete list of Houston-area public companies here.





